(S)-3-[(S)-2-((S)-1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-1-methyl-2-oxo-imidazolidine-4-carboxylic acid

Angiotensin converting enzyme (ACE) inhibitor. Antihypertensive.

Imidapril hydrochloride was used as a standard in bioequivalence test by LC/MS method.

antibiotic

ChEBI: Imidapril hydrochloride is a dipeptide.

Imidapril comprises large acyl moiety and is hydrolyzed by carboxylesterase (CES) 1.

Imidapril is a potent angiotensin converting enzyme inhibitor and anti-hypertensive.

Angiotensin-converting enzyme inhibitor:

Hypertension

Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
Antihypertensives: increased risk of hyperkalaemia, hypotension and renal failure with ARBs and aliskiren.
Bee venom extract: possible severe anaphylactoid reactions when used together.
Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
Cytotoxics: increased risk of angioedema with everolimus.
Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
Gold: flushing and hypotension with sodium aurothiomalate.
Lithium: reduced excretion, possibility of enhanced lithium toxicity.
Potassium salts: increased risk of hyperkalaemia.
Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

Imidapril is a prodrug, and is metabolised in the liver to the diacid imidaprilat, its active metabolite. The bioavailability of imidaprilat is about 42% after oral doses of imidapril.
About 40% of an oral dose is excreted in the urine, the rest in the faeces.